Fresenius Medical Care, the world’s leading provider of products and services for individuals with renal diseases, has successfully signed a new syndicated revolving credit facility with a group of 34 core relationship banks. It has a volume of EUR 2 billion with a term of five years plus two one-year extension options (“5+1+1” years) and can be drawn in different currencies.
The new credit facility replaces the existing USD 900 million and EUR 600 million revolving credit facilities, initially signed in 2012 and amended from time to time, and will serve as a backup line for general corporate purposes. The increased volume will further strengthen Fresenius Medical Care’s liquidity profile and enhance the company’s financial flexibility.
Supporting the company’s commitment to create value in ecological, social and economic terms, a sustainability component has been embedded in the credit facility. Based on this structure, the credit facility’s margin will rise or fall depending on the company's sustainability performance. This is Fresenius Medical Care’s first sustainability-linked financing instrument.
Helen Giza, Chief Financial Officer of Fresenius Medical Care, said: “With the refinancing of the credit agreement we have further optimized our financing structure. The new facility improves Fresenius Medical Care’s liquidity profile and gives us greater financial flexibility for our long-term growth strategy. It also extends our focus on sustainability to our financing instruments. By linking the new credit agreement to our sustainability efforts, we are underlining our integrated approach to sustainability throughout all aspects of the business.”